Dulera, what gives?

Quote












Anonymous said:
It's yesterdays drug at tomorrows price with no better outcomes, less indications and ass holes for a marketing team. Any other questions...oh the reps were really never trained to sell it right. God forbid it took one penny from Singulair
Click to expand...

When I sold Singulair against Advair, we discouraged combo use. Now we encourage it. Falseness at its best. It's all about our customers- NOT. It all depends on what Merck has to sell!
 












The problem is that merck retained more of their reps instead of keeping more SP reps. If this drug would've been launched by SP the numbers would be a lot better. Legacy Merck can't sell worth a sh@&!
 


















Actually my market share is growing weekly. How you ask? Very simple. I bribe a key allergist with speaker programs, and now his share is about 35%, and growing. So it's all very simple. just pick out a key allergist and bribe them with as many speaking engagements as you can set up. These docs are nothing but cheap, street-walking whores. Pay them, and they will perform.
 






























IF Merck reps can't sell Dulera like legacy SP folks could, then why have there been 3 launches with Asmanex??? and STILL no one knows about it -and 2 of those were before we merged.
 






Anonymous said:
IF Merck reps can't sell Dulera like legacy SP folks could, then why have there been 3 launches with Asmanex??? and STILL no one knows about it -and 2 of those were before we merged.
Click to expand...

in both cases, it is third in the class of inhaled steroid (without and with LABA). So, without a really demonstrable difference in efficacy or ease of use, why would you think it would do any better? Nothing more than a me too drug so, it captures only the 'leftover' market share.
 






Some of us have been spoiled by Merck for years with breakthrough drugs and top-notch management. Then we have the current Merck with constant layoffs. We should accept the fact and forget about how we were and realize we are a second or third class outfit. Then you will see Dulera as a "new" product and that is better than no product. Look at its success as keeping yourself employed a little bit longer and that fat paycheck keep coming for a few more months. Swallow your pride and go out, fight in the drenches, fight and sell. This was how we sold Pepcid being third in class with minimal benefits (if any) over Tagamet and Zantac. You made that silly little difference into a HUGE advantage. Some docs laughed. Some docs agreed. That guy selling the third XR version of generic Tricor does not bitch like some of us and he is making a great bonus right now. I have doubts if some of us, especially the whiners, can sell a product that require a shift in doc's thinking and kind of create a market at the same time like Fosamax and osteoporosis. Some of us would bitch about Merck bringing forth a product with ZERO demand because it required sweats to create the demand.
 






Anonymous said:
in both cases, it is third in the class of inhaled steroid (without and with LABA). So, without a really demonstrable difference in efficacy or ease of use, why would you think it would do any better? Nothing more than a me too drug so, it captures only the 'leftover' market share.
Click to expand...

There is money in a "leftover" market.
 






Anonymous said:
The problem is that merck retained more of their reps instead of keeping more SP reps. If this drug would've been launched by SP the numbers would be a lot better. Legacy Merck can't sell worth a sh@&!
Click to expand...

And the SP reps did such a fantastic job with Asmanex. Oh, and the marketing team for Dulera came from SP. Great job!
 






Anonymous said:
What is the problem with Dulera?
Click to expand...

The problem is that Dulera is the most successful drug launch we've had since Januvia was launched five years ago. When you most recent successful drug launch is the biggest piece of shit on the market, your company is in big trouble. Of course, you already know that.
 






Anonymous said:
in both cases, it is third in the class of inhaled steroid (without and with LABA). So, without a really demonstrable difference in efficacy or ease of use, why would you think it would do any better? Nothing more than a me too drug so, it captures only the 'leftover' market share.
Click to expand...

It might be the 3rd combo but there are many ICS on the market and all of them for many, many years- Azmacort, Pulmicort/Symbicort, Asmanex, Flovent, Maxair, Beclovent/Vanceril, etc. By my count it is at least the 7th and I might be leaving out a few.
 






Anonymous said:
And the SP reps did such a fantastic job with Asmanex. Oh, and the marketing team for Dulera came from SP. Great job!
Click to expand...

We did not know anything about asthma nor allergy when we launched Singulair either. Merck hired a lot of Astra Zeneca people to help out and get the reps trained as quickly as possible. Or brought in people from Eli Lilly to get us going in the antibiotics market. A good rep would sell even a piece of shit. Stop blaming others. Go Google "pet rock".
 






Top Bottom
Back
Quote